Hormonal
Pioglitazone improves NASH resolution and fibrosis stages in patients with T2DM and NAFLD, but its use is limited by side effects such as weight gain and bone fracture risk.
Pioglitazone is a diabetes medication that can also improve liver inflammation and fibrosis in fatty liver disease. However, it can cause weight gain, swelling, and increase the risk of bone fractures. It is generally used when other treatments are not suitable or effective, and the benefits for the liver must be weighed against these risks.
thiazolidinedione therapy was associated with amelioration of advanced fibrosis (OR: 3.15; CI: 1.25–7.93; p = 0.01), fibrosis of any stage (OR: 1.66; CI: 1.12–2.47; p = 0.01), and resolution of NASH (OR: 3.22; CI: 2.17–4.79; p < 0.001). Although the benefit of thiazolidinediones on NAFLD and NASH is well-established, their usage is limited now mainly because of their side effects, especially weight gain, lower limb edema, and high risk for bone fracture
Why this rating
Supported by data showing significant odds ratios for fibrosis and NASH resolution.
Source
Nonalcoholic Fatty Liver Disease and Its Complex Relation with Type 2 Diabetes Mellitus—From Prevalence to Diagnostic Approach and Treatment Strategies
Cosmina-Theodora Diaconu et al. · Journal of Clinical Medicine · 2022
DOI 10.3390/jcm11175144
More from this paper
- Weight loss of 7-10% of body weight leads to significant resolution of NASH and fibrosis regression in patients with NAFLD.Good
- GLP-1 receptor agonists (specifically Liraglutide and Semaglutide) promote NASH resolution and reduce hepatic steatosis in patients with T2DM and NAFLD, primarily through weight loss and reduced de novo lipogenesis.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →